ArticleCureus2025
Elevated Levels of Plasma Phosphorylated Tau 181 (pTau181) Associated With Opioid Use to Guide Medication Titration Over a Clinically Relevant Short Timescale.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe identification of many medications that delay neurodegeneration in animal models has created too many combinations to try in patients when time is short. We hypothesized that biomarkers of premature neuronal aging that are part of the amyloid-tau-neurodegeneration (ATN) profile, namely amyloid-β ratio, phosphorylated tau 181 (pTau181), and neurofilament light chain (NfL), could provide tools to optimize treatment in single-patient trials rapidly.
methodsWe retrospectively analyzed these biomarkers in patients with extensive neuropsychiatric polypharmacy and premature neuronal aging. We investigated whether ATN profile biomarkers were associated with age, gender, metabolic syndrome markers, and medication use. Additionally, two case reports provided examples of ATN biomarker application in clinical settings.
resultsWe identified 113 patients with plasma ATN profiles. Of 80 of those patients, clinical phenotypic data were available. Among these 80 patients, pTau181 was elevated in 31 (38.75%), amyloid-β ratio was below normal ranges in 11 (13.75%), and NfL was elevated in three (3.75%). The biomarkers correlated with age, as expected. Opioid use was significantly associated with pTau181 (p = 0.004) and NfL (p = 0.002), also after Bonferroni correction (both p < 0.05), but not with amyloid-β ratio. The biomarkers were not associated with other medication use.
conclusionIt is now possible to identify the overlaps between complex behavioral phenotypes (pain and cognition), plasma endophenotypes (ATN profile), and medication-targeted components of age-related pathophysiology. The current study provides a proof of concept; future research should focus on single-patient trials in patients with premature neuronal aging, where medication and dosage choices are based on individual ATN profiles. To facilitate such single-patient trials, funding is needed to promote the use of repurposed generic treatments, educate patients and providers regarding optimization principles, and continue developing sensitive biomarkers. Together, these can ensure the rapid progress of single-patient trials for treatment optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.